Market Overview

BioLineRx to Conduct Interim Analysis of Phase II/III CLARITY Trial of BL-1020


BioLineRx (NASDAQ: BLRX) announced today that it intends to conduct an interim analysis
of the Phase II/III CLARITY trial of BL-1020, a first in class, orally
available, GABA-enhanced antipsychotic for the treatment of
schizophrenia. The interim analysis, which is expected to be finalized
in the first quarter of 2013, will be performed on data of approximately
235 randomized patients from 27 sites in Romania and India. The primary
endpoint of the analysis will be the six-week effect of the drug on
cognitive function, which is a principal deficit in schizophrenia

Dr. Kinneret Savitsky, CEO of BioLineRx, stated, “The recent re-analysis
of BL-1020's EAGLE Phase IIb study, showing a substantially greater

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global


Related Articles (BLRX)

View Comments and Join the Discussion!